GlobeNewsWire
06 Aug 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a class action lawsuit alleging the use of channel stuffing to inflate revenue and undisclosed related party transactions. — Allegations of financial fraud and revenue manipulation typically lead to significant valuation write-downs and loss of investor trust.
-0.70Culper Research reported that ADMA Biologics' 2025 growth was a 'fiction,' claiming real growth was -3% compared to the reported 20%. — A massive discrepancy between reported and actual growth directly impacts the company's fundamental valuation.
-0.60Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral following concerns over the short-seller report. — Analyst downgrades from major institutions often trigger institutional selling and lower price targets.
-0.40Which stocks this story touches
Continue reading
6 related stories
Search tags
The company is facing a class action lawsuit alleging securities fraud, channel stuffing, and lack of internal controls, following a significant stock price decline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
6h ago
